Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTU NASDAQ:BCAX NASDAQ:EOLS NASDAQ:ETNB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$8.44+2.7%$7.10$5.47▼$11.99$170.52MN/A55,980 shs41,064 shsBCAXBicara Therapeutics$11.94+0.3%$10.64$7.80▼$28.09$649.84MN/A304,823 shs189,264 shsEOLSEvolus$7.63+1.5%$8.43$5.71▼$17.82$486.43M1.122.26 million shs472,060 shsETNB89BIO$9.03-4.1%$9.73$4.16▼$11.84$1.40B1.281.51 million shs3.09 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics+2.68%+0.96%+16.09%-25.70%+5.76%BCAXBicara Therapeutics+0.25%+0.84%+2.93%+28.66%+1,193,999,900.00%EOLSEvolus+1.46%-0.65%-14.84%-18.57%-51.83%ETNB89BIO-4.14%-4.24%-5.25%-9.25%+0.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABCAXBicara Therapeutics1.8131 of 5 stars3.50.00.00.01.80.80.6EOLSEvolus4.173 of 5 stars3.41.00.03.54.03.30.6ETNB89BIO2.2888 of 5 stars3.51.00.00.04.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 3.00Buy$20.33140.92% UpsideBCAXBicara Therapeutics 3.00Buy$32.25170.11% UpsideEOLSEvolus 2.80Moderate Buy$21.25178.51% UpsideETNB89BIO 3.00Buy$26.63194.85% UpsideCurrent Analyst Ratings BreakdownLatest ACTU, ETNB, EOLS, and BCAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025ACTUActuate TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.008/25/2025ACTUActuate TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.008/25/2025ETNB89BIOBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $29.008/22/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$41.00 ➝ $40.008/18/2025BCAXBicara TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$36.008/18/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.008/14/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)8/12/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.008/8/2025ETNB89BIORoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$12.00 ➝ $11.008/6/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $18.008/6/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$27.00 ➝ $20.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/A($0.13) per shareN/ABCAXBicara TherapeuticsN/AN/AN/AN/A$7.98 per shareN/AEOLSEvolus$266.27M1.85N/AN/A($0.29) per share-26.31ETNB89BION/AN/AN/AN/A$3.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$27.28MN/A0.00∞N/AN/AN/A-281.83%N/ABCAXBicara Therapeutics-$68M-$3.17N/AN/AN/AN/A-21.67%-20.89%11/11/2025 (Estimated)EOLSEvolus-$50.42M-$0.98N/AN/AN/A-22.31%-759.04%-24.63%11/5/2025 (Estimated)ETNB89BIO-$367.08M-$3.61N/AN/AN/AN/A-94.48%-80.92%11/6/2025 (Estimated)Latest ACTU, ETNB, EOLS, and BCAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ACTUActuate Therapeutics-$0.19-$0.30-$0.11-$0.30N/AN/A8/12/2025Q2 2025BCAXBicara Therapeutics-$0.54-$0.50+$0.04-$0.50N/AN/A8/7/2025Q2 2025ETNB89BIO-$0.49-$0.71-$0.22-$0.71N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/ABCAXBicara TherapeuticsN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A0.730.73BCAXBicara TherapeuticsN/A25.8025.80EOLSEvolus22.002.271.86ETNB89BIO0.0715.1915.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/ABCAXBicara TherapeuticsN/AEOLSEvolus90.69%ETNB89BION/AInsider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics69.34%BCAXBicara Therapeutics15.50%EOLSEvolus5.90%ETNB89BIO2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1020.75 million6.36 millionN/ABCAXBicara Therapeutics3254.56 million46.11 millionN/AEOLSEvolus17064.68 million60.87 millionOptionableETNB89BIO40148.31 million144.45 millionOptionableACTU, ETNB, EOLS, and BCAX HeadlinesRecent News About These CompaniesCharles Schwab Investment Management Inc. Grows Position in 89BIO $ETNBAugust 29 at 3:14 AM | marketbeat.com89bio to Participate in Upcoming Investor ConferencesAugust 28 at 4:05 PM | globenewswire.comAffinity Asset Advisors LLC Invests $1.27 Million in 89BIO $ETNBAugust 28 at 9:09 AM | marketbeat.comVanguard Group Inc. Acquires 1,471,278 Shares of 89BIO $ETNBAugust 28 at 3:11 AM | marketbeat.com89BIO (NASDAQ:ETNB) Given New $29.00 Price Target at Bank of AmericaAugust 27 at 1:09 PM | marketbeat.comNuveen LLC Makes New $7.53 Million Investment in 89BIO $ETNBAugust 27 at 3:38 AM | marketbeat.comSwiss National Bank Grows Stake in 89BIO $ETNBAugust 27 at 3:29 AM | marketbeat.comUniversity of Wisconsin Foundation Acquires 236,000 Shares of 89BIO $ETNBAugust 26, 2025 | marketbeat.com89bio price target lowered to $29 from $30 at BofAAugust 25, 2025 | msn.comCandriam S.C.A. Sells 223,838 Shares of 89BIO $ETNBAugust 24, 2025 | marketbeat.comErste Asset Management GmbH Has $6.50 Million Position in 89BIO $ETNBAugust 23, 2025 | marketbeat.comLord Abbett & CO. LLC Purchases New Shares in 89BIO (NASDAQ:ETNB)August 19, 2025 | marketbeat.com89BIO (NASDAQ:ETNB) Receives $26.29 Consensus PT from AnalystsAugust 19, 2025 | americanbankingnews.com89bio, Inc. (ETNB) Reports Second-Quarter Results; Leerink Partners and Citi Maintain ‘Buy’ RatingsAugust 19, 2025 | msn.com89BIO's (ETNB) "Sell (D-)" Rating Reiterated at Weiss RatingsAugust 16, 2025 | marketbeat.com89BIO (NASDAQ:ETNB) Given Consensus Recommendation of "Buy" by BrokeragesAugust 15, 2025 | marketbeat.com89BIO (NASDAQ:ETNB) Shares Down 5.2% After Analyst DowngradeAugust 12, 2025 | marketbeat.comFY2029 Earnings Estimate for 89BIO Issued By Leerink PartnrsAugust 12, 2025 | marketbeat.com89BIO (NASDAQ:ETNB) Releases Earnings Results, Misses Estimates By $0.22 EPSAugust 11, 2025 | marketbeat.com89bio: Promising As Pegozafermin Nears Phase 3 ReadoutAugust 11, 2025 | seekingalpha.com89BIO (NASDAQ:ETNB) Price Target Cut to $11.00 by Analysts at Royal Bank Of CanadaAugust 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025Amazon Enters Correction Zone: Time to Panic or Be Brave?By Sam Quirke | August 5, 2025Vertical Aerospace's New Deal and Earnings De-Risk ProductionBy Jeffrey Neal Johnson | August 5, 2025Vertical Aerospace: An Analyst's Roadmap to a Potential Re-RatingBy Jeffrey Neal Johnson | August 27, 2025ACTU, ETNB, EOLS, and BCAX Company DescriptionsActuate Therapeutics NASDAQ:ACTU$8.44 +0.22 (+2.68%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.45 +0.01 (+0.12%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Bicara Therapeutics NASDAQ:BCAX$11.94 +0.03 (+0.25%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$11.93 -0.01 (-0.08%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Evolus NASDAQ:EOLS$7.63 +0.11 (+1.46%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$7.64 +0.01 (+0.13%) As of 08/29/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.89BIO NASDAQ:ETNB$9.03 -0.39 (-4.14%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$9.03 0.00 (0.00%) As of 08/29/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
